NCT07119918尚未招募3 期
PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis (PICASSO): A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1 个研究点 分布在 1 个国家目标入组 5,276 人开始时间: 2025年9月1日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 5,276
- 试验地点
- 1
- 主要终点
- Any new stroke
研究概览
简要总结
An investigator-initiated, prospective, multicenter, randomized, double-blind, placebo-controlled trial comparing the 1-year incidence of stroke in patients with AIS or TIA within 7 days who are treated with either placebo or Recaticimab.
详细描述
This is an investigator-initiated, prospective, multicenter, randomized, double-blind, placebo-controlled trial to determine the efficacy of Recaticimab (PCSK9 inhibitor) administered within 7 days of symptom onset in patients with symptomatic intracranial atherosclerotic stenosis (sICAS) in reducing incident stroke within 1 year.
Study intervention: (1) Participants in the intervention group will receive Recaticimab 300mg subcutaneous Q8W for 1 year. (2) Participants in the control group will receive matched placebo subcutaneous Q8W for 1 year. All participants will receive best medical management (BMM), including intensive statins treatment and dual antiplatelet therapy.
A total of 5276 participants are anticipated to be recruited for this study. Eligible participants will be 1:1 randomly assigned to receive Recaticimab or placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥30 years and ≤80 years.
- •Patients aged between 30 to 49 are required to meet at least one of the following criteria:
- •Insulin dependent diabetes for at least 15 years.
- •At least 2 of the following atherosclerotic risk factors: hypertension (BP > 140/90 or on antihypertensive therapy); dyslipidemia (LDL > 130 mg /dL or HDL < 40 mg/dL or fasting triglycerides > 150 mg/dL or on lipid lowering therapy); smoking; non-insulin dependent diabetes or insulin dependent diabetes of less than 15 years duration; family history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery in parent or sibling who was < 55 years of age for men or < 65 for women at the time of the event.
- •History of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease.
- •Any stenosis of an extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by non-invasive vascular imaging or catheter angiography and is considered atherosclerotic.
- •Aortic arch atheroma documented by non-invasive vascular imaging or catheter angiography vi. any aortic aneurysm documented by non-invasive vascular imaging or catheter angiography that is considered atherosclerotic.
- •Diagnosed with acute ischemic stroke or moderate-to-high risk transient ischemic attack (ABCD2 score ≥4).
- •CTA or DSA confirmed intracranial atherosclerotic stenosis >50%, which was responsible for the incident.
- •The time from symptom onset to initiation of study treatment is within 7 days.
- •Signed informed consent.
排除标准
- •Baseline NIHSS ≥
- •Suspected cardiogenic ischemic cerebrovascular diseases (e.g., combined with atrial fibrillation, heart valve prosthesis, atrial myxoma, endocarditis, etc.).
- •Source of symptoms is possible related to ipsilateral carotid disease.
- •Other ischemic cerebrovascular diseases with specific causes (e.g., aortic dissection, vasculitis, vascular malformation, etc.).
- •Non-cerebral vascular disease (e.g., intracranial tumors, multiple sclerosis).
- •Hemorrhagic stroke or hemorrhagic transformation of cerebral infarction before randomization.
- •Pre-existing contraindications of using PCSK9 inhibitors.
- •Use of any PCSK9 inhibitors within the past 3 months.
- •Pregnant or childbearing-age women who have no effective contraceptives or positive pregnancy test records.
- •Patients who are participating in other trials.
- •Hepatic or renal dysfunction, defined as AST and/or ALT >3ULN，eGFR<30mL/min, or Crea >220μmol/L (2.5mg/dL).
- •Uncontrolled hypertension defined as systolic blood pressure (BP) >220mmHg or diastolic BP >120mmHg.
- •Life expectancy is less than 1 year due to severe non-cardiovascular disease.
- •Angioplasty or stenting procedure is planned before randomization.
- •Unable to finish the follow-up visit due to geographical factor or other reasons (e.g., dementia, alcoholism, substance abuse, severe mental disease, etc.)
研究组 & 干预措施
Placebo group
Placebo Comparator
干预措施: Placebo (Drug)
Recaticimab group
Experimental
干预措施: Recaticimab (Drug)
结局指标
主要结局
Any new stroke
时间窗: 1 year (±2) weeks
Any new ischemic or hemorrhagic stroke within 1 year
次要结局
- Quality of life (EQ-5D-5L)(1 year (±2) weeks)
- Composite cardiovascular events(1 year (±2) weeks)
- Ischemic stroke(1 year (±2) weeks)
- Hemorrhagic stroke(1 year (±2) weeks)
- Non-fatal stroke(1 year (±2) weeks)
- Myocardial infarction(1 year (±2) weeks)
- Death from cardiovascular causes(1 year (±2) weeks)
- NIHSS scores(7(±1) days or discharge)
- Modified Rankin Scale score at 90 days(90 (±14) days)
- Safety outcome: intracranial hemorrhage(1 year (±2) weeks)
- Modified Rankin Scale score at 1 year(1 year (±2) weeks)
- Safety outcome: Death(1 year (±2) weeks)
- Safety outcome: Serious Adverse Event (SAE)(1 year (±2) weeks)
研究者
Yamei Tang
Vice President of Sun Yat-sen Memorial Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
研究点 (1)
Loading locations...
相似试验
招募中
4 期
A Cohort Study Comparing PCSK9 Inhibitor Plus Statin With Statin Monotherapy for Carotid Artery StenosisCarotid Artery StenosisNCT07036991Changhai Hospital406
已完成
4 期
Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence TomographyRandomized Controlled TrialsNCT04851769Beijing Anzhen Hospital60
招募中
4 期
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial AtherosclerosisNCT06902740Peking Union Medical College Hospital300
终止
早期 1 期
PCSK9 Inhibition in Patients With Symptomatic Intracranial AtherosclerosisIntracranial AtherosclerosisIntraplaque HemorrhageStrokeNCT03507374University of Utah20
尚未招募
1 期
A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Efficacy of PCSK-9 Inhibitors in Delaying the Progression of Calcified Aortic Valve DiseaseAortic StenosisNCT06996223Nanfang Hospital, Southern Medical University316